Mogrify

Mogrify has developed proprietary technologies that can direct cellular reprogramming and the maintenance of cell identity, affecting a direct transdifferentiation from one mature cell type to another. This provides researchers with the template for turning human cells into any desired cell, even vital organs, potentially revolutionising treatments for degenerative diseases and transforming the lives of patients, with a current focus on ophthalmology, otology and metabolic disease.

CEO: Dr. Darrin M. Disley
Researchers: Professor Jose Polo at Monash University, Professor Owen Rackham at University of Bristol,  Professor Julian Gough at University of Bristol
Website: mogrify.co.uk